Related Experiment Videos
Abstract:
(1) Modafinil, a psychostimulant, has been available in France for the treatment of narcolepsy and idiopathic hypersomnia since 1994. (2) The initial clinical file was inadequate to judge its possible clinical value. (3) In narcolepsy three new short-term clinical trials have compared modafinil with a placebo (nearly 500 patients treated with modafinil). (4) These trials show that the effects of modafinil on daytime drowsiness are only moderate (average reduction of one unwanted sleep episode a day) but are subjectively better than those of a placebo. In all, 84% of patients preferred the modafinil period to the placebo period during a cross-over trial. In contrast, modafinil does not improve cataplexy. (5) No new trials have been done in idiopathic hypersomnia. (6) The effects of modafinil persist for at least four months according to a double-blind placebo-controlled trial. (7) The safety profile of modafinil appears to be similar to that of non amphetamine psychostimulants. (8) There is currently no evidence of dependence leading to withdrawal symptoms after abrupt treatment cessation, or of a risk of abuse.
Insights
Modafinil offers moderate improvement for daytime drowsiness in narcolepsy patients, with most preferring it over placebo. Its long-term effects and safety profile are comparable to other psychostimulants.
Area of Science:
- Neurology
- Pharmacology
Background:
- Modafinil, a psychostimulant, has been used in France since 1994 for narcolepsy and idiopathic hypersomnia.
- Initial clinical data were insufficient to fully assess its therapeutic value.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of modafinil for treating narcolepsy and idiopathic hypersomnia.
- To assess the subjective and objective improvements in daytime drowsiness and cataplexy.
Main Methods:
- Three short-term clinical trials compared modafinil to placebo in nearly 500 narcolepsy patients.
- A double-blind, placebo-controlled trial assessed the persistence of modafinil's effects over four months.
- Safety profiles were compared to non-amphetamine psychostimulants.
Main Results:
- Modafinil demonstrated moderate improvement in daytime drowsiness, reducing sleep episodes by an average of one per day.
- 84% of patients preferred modafinil over placebo in a cross-over trial, indicating subjective benefit.
- Modafinil did not show efficacy in improving cataplexy and no new trials were conducted for idiopathic hypersomnia.
Conclusions:
- Modafinil provides subjective and moderate objective benefits for daytime drowsiness in narcolepsy.
- The drug's effects persist for at least four months with a safety profile similar to other psychostimulants.
- No evidence of dependence or abuse potential was observed with modafinil treatment cessation.